319 related articles for article (PubMed ID: 17483335)
21. Expression and secretion of neuroleukin/phosphohexose isomerase/maturation factor as autocrine motility factor by tumor cells.
Niinaka Y; Paku S; Haga A; Watanabe H; Raz A
Cancer Res; 1998 Jun; 58(12):2667-74. PubMed ID: 9635595
[TBL] [Abstract][Full Text] [Related]
22. Thyroid transcription factor-1 inhibits transforming growth factor-beta-mediated epithelial-to-mesenchymal transition in lung adenocarcinoma cells.
Saito RA; Watabe T; Horiguchi K; Kohyama T; Saitoh M; Nagase T; Miyazono K
Cancer Res; 2009 Apr; 69(7):2783-91. PubMed ID: 19293183
[TBL] [Abstract][Full Text] [Related]
23. A small interfering RNA targeting osteopontin as gastric cancer therapeutics.
Gong M; Lu Z; Fang G; Bi J; Xue X
Cancer Lett; 2008 Dec; 272(1):148-59. PubMed ID: 18694621
[TBL] [Abstract][Full Text] [Related]
24. Down-regulation of phosphoglucose isomerase/autocrine motility factor enhances gensenoside Rh2 pharmacological action on leukemia KG1α cells.
You ZM; Zhao L; Xia J; Wei Q; Liu YM; Liu XY; Chen DL; Li J
Asian Pac J Cancer Prev; 2014; 15(3):1099-104. PubMed ID: 24606425
[TBL] [Abstract][Full Text] [Related]
25. Inhibitory effect of DA-125, a new anthracyclin analog antitumor agent, on the invasion of human fibrosarcoma cells by down-regulating the matrix metalloproteinases.
Park HJ; Chung HJ; Min HY; Park EJ; Hong JY; Kim WB; Kim SH; Lee SK
Biochem Pharmacol; 2005 Dec; 71(1-2):21-31. PubMed ID: 16271263
[TBL] [Abstract][Full Text] [Related]
26. miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon.
Gandellini P; Folini M; Longoni N; Pennati M; Binda M; Colecchia M; Salvioni R; Supino R; Moretti R; Limonta P; Valdagni R; Daidone MG; Zaffaroni N
Cancer Res; 2009 Mar; 69(6):2287-95. PubMed ID: 19244118
[TBL] [Abstract][Full Text] [Related]
27. Autocrine motility factor signaling enhances pancreatic cancer metastasis.
Tsutsumi S; Yanagawa T; Shimura T; Kuwano H; Raz A
Clin Cancer Res; 2004 Nov; 10(22):7775-84. PubMed ID: 15570012
[TBL] [Abstract][Full Text] [Related]
28. Characterization of E-cadherin-dependent and -independent events in a new model of c-Fos-mediated epithelial-mesenchymal transition.
Mejlvang J; Kriajevska M; Berditchevski F; Bronstein I; Lukanidin EM; Pringle JH; Mellon JK; Tulchinsky EM
Exp Cell Res; 2007 Jan; 313(2):380-93. PubMed ID: 17141758
[TBL] [Abstract][Full Text] [Related]
29. Autocrine motility factor/glucose-6-phosphate isomerase is a possible predictor of metastasis in bone and soft tissue tumours.
Dobashi Y; Watanabe H; Matsubara M; Yanagawa T; Raz A; Shimamiya T; Ooi A
J Pathol; 2006 Jan; 208(1):44-53. PubMed ID: 16294294
[TBL] [Abstract][Full Text] [Related]
30. Down-regulation of Cx43 by retroviral delivery of small interfering RNA promotes an aggressive breast cancer cell phenotype.
Shao Q; Wang H; McLachlan E; Veitch GI; Laird DW
Cancer Res; 2005 Apr; 65(7):2705-11. PubMed ID: 15805269
[TBL] [Abstract][Full Text] [Related]
31. Suppression of AMF/PGI-mediated tumorigenic activities by ursolic acid in cultured hepatoma cells and in a mouse model.
Shih WL; Yu FL; Chang CD; Liao MH; Wu HY; Lin PY
Mol Carcinog; 2013 Oct; 52(10):800-12. PubMed ID: 22549898
[TBL] [Abstract][Full Text] [Related]
32. Loss of type III transforming growth factor beta receptor expression increases motility and invasiveness associated with epithelial to mesenchymal transition during pancreatic cancer progression.
Gordon KJ; Dong M; Chislock EM; Fields TA; Blobe GC
Carcinogenesis; 2008 Feb; 29(2):252-62. PubMed ID: 17999987
[TBL] [Abstract][Full Text] [Related]
33. Focal adhesion kinase regulates syndecan-2-mediated tumorigenic activity of HT1080 fibrosarcoma cells.
Park H; Han I; Kwon HJ; Oh ES
Cancer Res; 2005 Nov; 65(21):9899-905. PubMed ID: 16267014
[TBL] [Abstract][Full Text] [Related]
34. Induction of hepatoma cells migration by phosphoglucose isomerase/autocrine motility factor through the upregulation of matrix metalloproteinase-3.
Yu FL; Liao MH; Lee JW; Shih WL
Biochem Biophys Res Commun; 2004 Jan; 314(1):76-82. PubMed ID: 14715248
[TBL] [Abstract][Full Text] [Related]
35. Small interfering RNA-directed targeting of Toll-like receptor 4 inhibits human prostate cancer cell invasion, survival, and tumorigenicity.
Hua D; Liu MY; Cheng ZD; Qin XJ; Zhang HM; Chen Y; Qin GJ; Liang G; Li JN; Han XF; Liu DX
Mol Immunol; 2009 Sep; 46(15):2876-84. PubMed ID: 19643479
[TBL] [Abstract][Full Text] [Related]
36. Antihuman epidermal growth factor receptor 2 antibody herceptin inhibits autocrine motility factor (AMF) expression and potentiates antitumor effects of AMF inhibitors.
Talukder AH; Bagheri-Yarmand R; Williams RR; Ragoussis J; Kumar R; Raz A
Clin Cancer Res; 2002 Oct; 8(10):3285-9. PubMed ID: 12374700
[TBL] [Abstract][Full Text] [Related]
37. The growth and metastasis of human hepatocellular carcinoma xenografts are inhibited by small interfering RNA targeting to the subunit ATP6L of proton pump.
Lu X; Qin W; Li J; Tan N; Pan D; Zhang H; Xie L; Yao G; Shu H; Yao M; Wan D; Gu J; Yang S
Cancer Res; 2005 Aug; 65(15):6843-9. PubMed ID: 16061667
[TBL] [Abstract][Full Text] [Related]
38. Inhibition mechanism of cytokine activity of human autocrine motility factor examined by crystal structure analyses and site-directed mutagenesis studies.
Tanaka N; Haga A; Uemura H; Akiyama H; Funasaka T; Nagase H; Raz A; Nakamura KT
J Mol Biol; 2002 May; 318(4):985-97. PubMed ID: 12054796
[TBL] [Abstract][Full Text] [Related]
39. Raft-dependent endocytosis of autocrine motility factor/phosphoglucose isomerase: a potential drug delivery route for tumor cells.
Kojic LD; Wiseman SM; Ghaidi F; Joshi B; Nedev H; Saragovi HU; Nabi IR
PLoS One; 2008; 3(10):e3597. PubMed ID: 18974847
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1.
Ramer R; Hinz B
J Natl Cancer Inst; 2008 Jan; 100(1):59-69. PubMed ID: 18159069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]